CV benefit of daily statin therapy in the HOPE-3 trial

Media formats available:

Preventive PCI versus only optimal medical therapy for vulnerable plaques
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC.24
Preventive PCI versus only optimal medical therapy for vulnerable plaques
- Marc Bonaca, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC.24
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
- Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
The effect of icosapent ethyl on CV events in metabolic syndrome
Diabetes
The effect of icosapent ethyl on CV events in metabolic syndrome
- Michael Miller, MD

PACE-CME